Pancreatic and Hepatic Oncology Research

DEVELOPMENT OF A CONSENSUS MOLECULAR CLASSIFIER FOR PANCREATIC DUCTAL ADENOCARCINOMA

This paper develops a consensus molecular classifier for pancreatic ductal adenocarcinoma by integrating tumor and stroma features, achieving high accuracy in predicting overall survival.

Local glucocorticoid signalling promotes pancreatic cancer

This study identifies Hsd11b1 as a key enzyme promoting glucocorticoid signaling in pancreatic cancer, contributing to immunosuppression and fibrosis, suggesting HSD11B1 as a therapeutic target.

Leakage-Safe Cross-Cohort Transcriptomic Survival Analysis in Pancreatic Ductal Adenocarcinoma: A Corrected Reanalysis

The paper reanalyzes transcriptomic survival data in PDAC using corrected methods, finding no validated transportable prognostic model or five-gene biomarker panel across cohorts.

Single-cell Transcriptomic Profiling of Pancreatic Ductal Adenocarcinoma: Epithelial Reprogramming and Systemic Immune Exhaustion

This study uses scRNA-seq to analyze PDAC tumor and blood cells, revealing epithelial reprogramming and systemic immune exhaustion as key features of the disease.

Therapeutic Eradication of Cancer-associated Fibroblasts Inhibits in vivo progression of Pancreatic Cancer

This study shows that clemastine eradicates cancer-associated fibroblasts, halts pancreatic cancer progression, and synergizes with gemcitabine to inhibit metastasis.

Spatial Conformation of Pancreatic Cancer Is Associated with Disease Recurrence after Curative-Intent Total Neoadjuvant Therapy

This paper quantifies spatial cancer-stroma topology in post-TNT PDAC and shows it independently predicts disease-free survival better than traditional response assessments.

Integrative analysis of genomic and transcriptomic data informs precancer progression in the pancreas

The paper identifies multi-omic phenotypes in pancreatic precursor lesions to distinguish progressive from indolent precancers using integrative transcriptomic, genomic, and spatial data.

Nischarin agonist rilmenidine shows antimetastatic potential in pancreatic ductal adenocarcinoma

This study investigates the antimetastatic potential of Nischarin agonist rilmenidine in pancreatic ductal adenocarcinoma using in vitro and in vivo models.

Tumor-intrinsic MHC-II activation in pancreatic ductal adenocarcinoma enhances immune response and treatment efficacy

This study shows that MHC-II expression in pancreatic cancer cells correlates with immune infiltration and improves immunotherapy response in mouse models.

ZEB1, a novel regulator of Junctional Adhesion Molecule A, impacts sensitivity of pancreatic cancer-associated fibroblasts to oncolytic reovirus

This study identifies ZEB1 as a regulator of JAM-A expression in pancreatic fibroblasts, showing that ZEB1 inhibition enhances reovirus sensitivity in these cells.

Integrated spatial morpho-transcriptomics predicts functional traits in pancreatic cancer

The paper integrates spatial morpho-transcriptomics to identify morphological subtypes in pancreatic cancer cell lines and tissues, linking them to gene expression, drug resistance, and metastatic potential.

Modulating p38MAPK recalibrates sensitivity of drug-resistant pancreatic adenoductal carcinoma cells toward chemotherapy and correlate with improved outcome in PDAC patients: Experimental and metadata evidence

This paper shows that inhibiting p38MAPK increases sensitivity of drug-resistant pancreatic cancer cells to chemotherapy and correlates with better patient outcomes.

Integrated cell atlas and tumoroids chart pancreatic cancer therapeutic targets

The paper integrates single-cell transcriptomes and spatial transcriptomics to identify therapeutic targets in pancreatic cancer by analyzing cell states and ligand-receptor interactions in tumoroids.

DUSP6 is upregulated in metastasis and influences migration and metabolism in pancreatic cancer cells

This study shows DUSP6 is upregulated in pancreatic cancer metastasis and independently influences cell migration and metabolism, suggesting it as a therapeutic target.

PDAC tumor immune system escape architecture: Analysis of transcriptomics of mechanisms that TME is tackling immune system in Pancreatic Ductal Adenocarcinoma Tumors

The paper analyzes single-cell RNA sequencing data from PDAC patients to uncover immune evasion mechanisms and TME heterogeneity in pancreatic ductal adenocarcinoma.

Exploiting TGF-β-mediated Stromal Programming in Homologous Recombination-Deficient Pancreatic Cancer

This study shows that ATM-deficient pancreatic cancers reprogram the tumor microenvironment via TGF-β-driven myCAF enrichment, and targeting this stromal axis with chemotherapy improves therapeutic efficacy.

Radiotherapy drives lung metastasis in PDAC via a RhoGTPasesignaling shift towards MRCK-dependency

This study shows that radiotherapy promotes lung metastasis in PDAC by increasing MRCK activity, which can be inhibited by BDP9066.

Molecular Magnetic Resonance Imaging of Dysregulated Zinc Secretion Detects Early Pancreatic Ductal Adenocarcinoma Lesions and Response to KRASG12D Inhibitor Treatment

This study uses SSZS MRI to detect early PDAC lesions and monitor treatment response and recurrence.

Tumor nutrient stress gives rise to a drug tolerant cell state in pancreatic cancer

This study shows that pancreatic cancer cells in a nutrient-stressed tumor microenvironment develop drug tolerance, and identifies BCL-XL inhibition as a potential therapeutic strategy.

MondoA mediates transcriptional coordination between the MYC network and the integrated stress response in pancreatic ductal adenocarcinoma

This paper shows MondoA is essential for MYC-driven pancreatic cancer survival by coordinating MYC network activity with the integrated stress response, and small-molecule inhibition of MondoA kills cancer cells.

Multi-omic profiling of intraductal papillary neoplasms of the pancreas reveals distinct expression patterns and potential markers of progression

This study profiles proteins and glycoproteins in pancreatic neoplasms to identify expression patterns and potential progression markers.

The Pdgfd-Pdgfrb axis orchestrates tumor-nerve crosstalk in pancreatic cancer

This study identifies Pdgfd-Pdgfrb signaling as a driver of perineural invasion in pancreatic cancer by promoting cancer cell invasiveness and nerve engagement.

Integrating multi-modal transcriptomics identifies cellular subtypes with distinct roles in PDAC progression

The paper integrates multi-modal transcriptomics to identify PDAC-associated cellular subtypes and their prognostic roles.

Orai3 orchestrates gemcitabine resistance in pancreatic cancer via NFATc1-SLIT3 axis

This paper identifies Orai3 as a driver of gemcitabine resistance in pancreatic cancer through the Orai3-NFATc1-SLIT3 signaling pathway, showing its role in cell proliferation, apoptosis, and metastasis.

In-depth proteomic profiling of the extracellular matrix of pancreatic ductal adenocarcinomas identifies signatures correlating with lymphocyte infiltration

This study identifies ECM protein signatures in PDAC that correlate with CD8+ T-cell infiltration and patient survival.

Integrated spatial proteomics of human PDAC uncovers an expanded tumour-immune-stroma spectrum with genomic associations

This study integrates spatial proteomics and genomics in PDAC to identify tumour-immune-stroma interactions and their genomic associations, showing multi-omics models improve patient survival prediction.

Tumour genotype shapes blood biomarker expression for use in pancreatic cancer detection and diagnosis.

This study shows that genetic mutations in PDAC affect blood biomarker profiles, suggesting genotype-specific biomarkers are needed for early detection.

Form Follows Function: A New Paradigm of Pancreatic Cancer Progression

This paper identifies geometric and spatial patterns in pancreatic cancer that correlate with aggressive behavior and develops an AI tool to improve clinical evaluation and treatment planning.

ZBTB11 Depletion Targets Metabolic Vulnerabilities in K-Ras Inhibitor Resistant PDAC

This study develops ZBTB11 degraders to target metabolic vulnerabilities in K-Ras inhibitor-resistant PDAC, showing improved anti-cancer activity with reduced toxicity to neurons.

SpheroMap Cytometry: a novel spatial flow cytometry approach to evaluate immune response in PDAC spheroids

This paper introduces SpheroMap Cytometry, a spatial flow cytometry method to analyze immune cell infiltration in PDAC spheroids, revealing hypoxia-driven changes in T-cell distribution and function.